Hyperfine Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Hyperfine şirketinin toplam hissedar öz sermayesi $58.3M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $69.4M ve $11.1M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$45.77m
Eşitlik	US$58.32m
Toplam yükümlülükler	US$11.06m
Toplam varlıklar	US$69.39m

Son finansal sağlık güncellemeleri

Hyperfine (NASDAQ:HYPR) Is In A Good Position To Deliver On Growth Plans

Apr 04

Recent updates

Analysts Are Updating Their Hyperfine, Inc. (NASDAQ:HYPR) Estimates After Its Third-Quarter Results

Nov 15

Hyperfine appoints Maria Sainz as President, CEO

Oct 06

Hyperfine GAAP EPS of -$0.33 misses by $0.06, revenue of $1.53M misses by $0.47M

Aug 10

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: HYPR 'nin kısa vadeli varlıkları ( $64.1M ) kısa vadeli yükümlülüklerini ( $10.0M ) aşıyor.

Uzun Vadeli Yükümlülükler: HYPR şirketinin kısa vadeli varlıkları ( $64.1M ) uzun vadeli yükümlülüklerini ( $1.1M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: HYPR borçsuzdur.

Borcun Azaltılması: HYPR un 5 yıl önce borcu yoktu.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: HYPR şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: HYPR serbest nakit akışı her yıl % 9.9 1.1 yıl yetecek nakit akışına sahip olacaktır.

Hyperfine Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Hyperfine Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Inclusion on the Nasdaq Global Market

Hyperfine Notifies the Nasdaq Listing Qualifications Staff

Hyperfine (NASDAQ:HYPR) Is In A Good Position To Deliver On Growth Plans

Recent updates

Analysts Are Updating Their Hyperfine, Inc. (NASDAQ:HYPR) Estimates After Its Third-Quarter Results

Hyperfine, Inc. Updates Revenue Guidance for the Year 2024

Hyperfine, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Hyperfine, Inc. Revises Revenue Guidance for the Year 2024

Hyperfine, Inc. Revises Revenue Guidance for the Year 2024

Hyperfine Announces Presentation of Initial Data from Observational Clinical Studies Evaluating the Use of Portable MR Brain Imaging for Alzheimer's Patients

Hyperfine, Inc. Announces FDA Clearance of Software Update That Enables Faster Acquisition of Best-In-Class Ultra-Low-Field Brain Images

Hyperfine, Inc. Highlights Positive Results from Multi-Site Observational Study on Swoop® System for Stroke Assessment

Hyperfine, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Hyperfine Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Inclusion on the Nasdaq Global Market

Hyperfine, Inc. Provides Earnings Guidance for the Year 2024

Hyperfine, Inc. to Report Q1, 2024 Results on May 13, 2024

Hyperfine, Inc., Annual General Meeting, Jun 11, 2024

Hyperfine, Inc. Enroll First Alzheimer's Patients Receiving Amyloid-Targeting Therapy in Care PMR Study

Hyperfine, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024

Hyperfine, Inc. Launches AI-Powered Brain Imaging Software for Enhanced Image Quality and Ease of Use

Hyperfine, Inc. Provides Earnings Guidance for the Full Year 2023

Hyperfine, Inc. Completes Enrollment for Hope Pmr Pediatric Hydrocephalus Study Using Hyperfine, Inc. Portable Mr. Imaging System

Hyperfine, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Hyperfine, Inc. Announces Executive Changes

Hyperfine, Inc. Provides Earnings Guidance for the Year 2023

Hyperfine, Inc. Announces FDA Clearance for Improved AI-Powered Software and Expanded Field of View for the Swoop Portable MR Imaging System

Hyperfine, Inc. Announces New Data Regarding the Use of the Swoop System in Stroke Patient Follow-Up

Hyperfine, Inc. Announces Chief Financial Officer Changes

Hyperfine, Inc. Announces Termination of Neela Paykel as General Counsel, Chief Compliance Officer, and Corporate Secretary

Hyperfine Notifies the Nasdaq Listing Qualifications Staff

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Hyperfine, Inc. Provides Revenue Guidance for the Full Year of 2022

Hyperfine, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Hyperfine Names Maria Sainz as Chief Executive Officer, Effective October 24, 2022

Hyperfine appoints Maria Sainz as President, CEO

Consensus forecasts updated

Founder & Vice Chairman recently bought US$442k worth of stock

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Hyperfine, Inc. Provides Revenue Guidance for the Full Year of 2022

Hyperfine GAAP EPS of -$0.33 misses by $0.06, revenue of $1.53M misses by $0.47M

Hyperfine, Inc. to Report Q2, 2022 Results on Aug 10, 2022

Hyperfine, Inc. Announces Zero Radiation Dose Rapid MR Imaging Test for Pediatric Hydrocephalus Patients

Hyperfine, Inc. Announces Executive Changes, Effective July 29, 2022

Hyperfine stock plunges 14% as CEO Dave Scott steps down

Founder & Vice Chairman recently bought US$119k worth of stock

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Hyperfine, Inc. Provides Revenue Guidance for the Full Year 2022

High number of new and inexperienced directors

Hyperfine, Inc., Annual General Meeting, Jun 08, 2022

Hyperfine, Inc. to Report Q1, 2022 Results on May 11, 2022

Hyperfine (NASDAQ:HYPR) Is In A Good Position To Deliver On Growth Plans

Hyperfine: MR Imaging In A Swoop

Hyperfine, Inc. to Report Q4, 2021 Results on Mar 23, 2022

Hyperfine Appoints Chip Truwit, M.D. as Senior Medical Director

Hyperfine, Inc. Provides Unaudited Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2021

Hyperfine, Inc. announced a financing transaction

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin